Market Overview

UPDATE: Bank of America Reiterates Buy Rating, Lowers PT on Vivus on Failed Qsiva Appeal

Related VVUS
Neothetics' Fat Reduction Candidate Fails in Phase II Study
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

In a report published Friday, Bank of America reiterated its Buy rating on Vivus (NASDAQ: VVUS), but lowered its price target from $30.00 to $26.00.

Bank of America noted, “VVUS has announced that the EU regulatory agency (CHMP) confirmed its October 2012 decision to decline approval for the company's weight loss drug Qsiva (Qsymia in the US) without a pre-approval cardiovascular outcomes trial (CVOT) to establish long-term safety. VVUS management does not plan to pursue further action on this ruling but may pursue other ex-US opportunities and could re-visit EU approval with interim data from its US-required post approval CVOT. We had assumed a low probability of approval in the EU, given continued caution in that region on prescription weight loss medications. Removing our ex-US royalty estimates lowered our NPV by ~$3/share. While our DCF-derived PO is now $26 ($30 previously), our favorable outlook for VVUS is unchanged.”

Vivus closed on Thursday at $12.88.

Latest Ratings for VVUS

Feb 2016RBC CapitalDowngradesOutperformSector Perform
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (VVUS)

View Comments and Join the Discussion!

Partner Center